Immunoglobulin-specific responses to chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection

Journal of Infectious Diseases

Volumn 206, Issue 12, 2012, Pages 1836-1843

  Geisler, William M ^a   Morrison, Sandra G ^c   Doemland, Martha L ^d   Iqbal, Shehzad M ^e   Su, Jin ^e   Mancevski, Ausra ^e   Hook, Edward W ^a,b   Morrison, Richard P ^c  

^a University of Alabama at Birmingham   (United States)

^b Jefferson County Department of Health   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d SANOFI PASTEUR   (France)

^e Sanofi Pasteur   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ANTIBODY RESPONSE; ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CROSS REACTION; ELEMENTARY BODY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL TRACT INFECTION; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SEROPREVALENCE; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUPS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84870227307     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis621     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta, US: Department of Health and Human Services, 2011.
2. Centers for Disease Control and Prevention. CDC Grand Rounds: Chlamydia prevention: Challenges and strategies for reducing disease burden and sequelae. MMWR 2011; 60:370-3.
3. Geisler WM. Duration of untreated uncomplicated genital Chlamydia trachomatis infection and factors associated with chlamydia resolution: A review of human studies. J Infect Dis 2010; 201:S104-13.
4. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydia infection. NEJM 1996; 334:1362-6. (Pubitemid 26152715)
5. Centers for Disease Control and Prevention. Chlamydia screening among sexually active young female enrollees of health plans - United States, 2000-2007. MMWR 2009; 58:362-5.
6. Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccineinduced immunity to Chlamydia muridarum genital infection. Infect Immun 2010; 78:4374-83.
7. Morrison SG, Morrison RP. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005; 175:7536-42. (Pubitemid 41713452)
8. Morrison SG, Su H, Caldwell HD, Morrison RP. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells. Infect Immun 2000; 68:6979-87. (Pubitemid 32463411)
9. Belshe RB, Leone PA, Bernstein DI, et al. Herpevac trial for women: Efficacy results of a trial of a herpes simplex vaccine. NEJM 2012; 366:34-43.
10. Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981; 31:1161-76. (Pubitemid 11155484)
11. Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class IIrestricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995; 63:4661-8.
12. Frey A, Canzio JD, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998; 221:35-41. (Pubitemid 29017921)
13. Bax CJ, Mutsaers JA, Jansen CL, Trimbos JB, Dorr PJ, Oostvogel PM. Comparison of serologic assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynecological patients. Clin Diag Lab Immunol 2003; 10:174-6. (Pubitemid 36133847)
14. Gorander S, Lagergard T, Romanik M, Viscidi RP, Martirosian G, Liljeqvist JA. Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland. Clin Vaccine Immunol 2008; 15:675-80. (Pubitemid 351972727)
15. Jonsson M, Karlsson R, Persson K, et al. The influence of sexual and social factors on the risk of Chlamydia trachomatis infections: A population- based serologic study. Sex Trans Dis 1995; 22:355-63.
16. Lyytikainen E, Kaasila M, Koskela P, et al. Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. Sex Transm Infect 2008; 84:19-22. (Pubitemid 351195845)
17. Verkooyen RP, Peeters MF, van Rijsoort-Vos JH, van der Meijden WI, Mouton JW. Sensitivity and specificity of three new commercially available Chlamydia trachomatis tests. Internatl J STD AIDS 2002; 13 (Suppl 2):23-25. (Pubitemid 35417215)
18. Caterino-de-Araujo A, de-los-Santos Fortuna E. Seropositivity to Chlamydia trachomatis in prostitutes: Relationship to other sexually transmitted diseases (STDs). Braz J Med Biolog Res 1990; 23:697-700.
19. Paroli E, Franco E, Mele A, et al. Seroprevalence of anti-Chlamydia trachomatis IgG in outpatients attending a sexually transmitted disease clinic in Italy. Eur J Epidemiol 1990; 6:329-31. (Pubitemid 20346713)
20. Morre SA, Munk C, Persson K, et al. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol 2002; 40:584-7. (Pubitemid 34130884)
21. Wills GS, Horner PJ, Reynolds R, et al. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol 2009; 16:835-43.
22. Wang S-P, Grayston JT. Human serology in Chlamydia trachomatis infection with microimmunofluorescence. J Infect Dis 1974; 130: 388-97.
23. Gilbert P, Wang M, Wrin T, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202:595-605.
24. Kennedy RB, Ovsyannikova IG, Pankratz VS, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009; 27:3319-23.
25. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L. HIV vaccine trials network. Demographic factors that influence the neutralizing antibody response in recipients of HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-9. (Pubitemid 39564702)
26. Clark MR. IgG effector mechanisms. Chem Immunol 1997; 65:88-110. (Pubitemid 27029828)
27. Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004; 172:2731-8. (Pubitemid 38263654)
28. Morrison SG, Farris CM, Sturdevant GL, Whitmire WM, Morrison RP. Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity. J Infect Dis 2011; 203:1120-8.